不久，全世界仿制药第一大佬，辉瑞和Mylan取名为Viatris！

新政策法规下品质本年度回望年报规章制度及加工工艺变更管理重中之重培圳：药品研发质量管理体系创建化学原料药制取加工工艺科学研究2020版中国药典有关讲解与各处难题实践活动剖析November 12, 2019 - 12:15pm EST最新动态，辉瑞普强（Upjohn）和迈蓝（Mylan）公布合拼的企业名叫Viatris（拼音发音为‘viǝ-trīs）。预估在2020半年度进行交易，到时候仿制药大佬将以Viatris姓名出現。2019年7月29日，迈蓝和辉瑞公布了下列最后协议书：将迈蓝与辉瑞主打产品专利权期满知名品牌和仿制药各个部门—普强合拼，以建立一家新的全世界制药公司。依据构造为全个股、反方向莫里斯相信交易的协议书条文，每股迈蓝个股将转化成新公司的一股个股。辉瑞公司股东将有着合拼后新公司57％的股权，而迈蓝公司股东将有着43％的股权。根据将2个高宽比相辅相成的业务流程的融合，新公司将转型发展并加速分别业务流程考虑病人要求的业务水平，拓展她们在超出165个销售市场的能力。迈蓝为每个重要医治行业，如中枢系统和麻药、传染性疾病和心脑血管疾病产生多样化的产品组合策略，及其强劲的商品管道、高品质的生产制造与物流系统优点。普强则产生了可信赖的代表性知名品牌，如立普妥（阿托伐他汀钙）、西乐葆（塞来昔布）和伟哥（他达那非）等，及其业经证实的产品化能力，包含在我国和别的新兴经济体的领导干部影响力。本次交易将使新公司明显拓展迈蓝目前普遍产品组合策略的地域覆盖面积和将来商品管道——包含在繁杂仿制药和微生物相近方子应对普强现阶段有着市场销售基础设施建设和本地销售市场技术专业工作经验的新提高销售市场开展重特大项目投资 。交易关键点PPT:附全文HERTFORDSHIRE, England & PITTSBURGH & Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs).Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.“We wanted a name that would differentiate our new company and clearly explain how we will be a champion for global health,” said Robert J. Coury, who will serve as Executive Chairman of the new company, as previously announced. “We are creating a company unlike any other – a company focused on building a more hopeful and sustainable healthcare journey, empowering patients to live healthier at every stage of life.”“The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced. “We have an opportunity to deliver better health, better care and better value for patients and partners around the world.”Formed through a combination of two highly complementary businesses, Viatris will unite Upjohn’s strong leadership position in China and emerging markets with Mylan’s significant presence in the U.S. and Europe, allowing the new company to have a meaningfully expanded geographic reach for Viatris’ broad product portfolio and future pipeline.It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn. More information regarding Viatris, including the company’s full executive management team, board of directors, stock symbol, and logo will be available at a later date.Customers and patients will continue to be served by the Mylan and Upjohn brands for the near future. The new name will be effective upon closing of the combination, which is expected to occur in mid-2020. The two companies will continue to operate as independent, separate organizations until close.Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, and being a trusted partner for the healthcare community worldwide.“We wanted a name that would differentiate our new company and clearly explain how we will be a champion for global health,” said Robert J. Coury, who will serve as Executive Chairman of the new company, as previously announced. “We are creating a company unlike any other – a company focused on building a more hopeful and sustainable healthcare journey, empowering patients to live healthier at every stage of life.”“The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible,” said Michael Goettler, Group President, Upjohn, who will serve as Chief Executive Officer of Viatris, as previously announced. “We have an opportunity to deliver better health, better care and better value for patients and partners around the world.”Formed through a combination of two highly complementary businesses, Viatris will unite Upjohn’s strong leadership position in China and emerging markets with Mylan’s significant presence in the U.S. and Europe, allowing the new company to have a meaningfully expanded geographic reach for Viatris’ broad product portfolio and future pipeline.It is expected that in the coming months, shareholders of Mylan will vote on the proposed combination of Mylan and Upjohn. More information regarding Viatris, including the company’s full executive management team, board of directors, stock symbol, and logo will be available at a later date.Customers and patients will continue to be served by the Mylan and Upjohn brands for the near future. The new name will be effective upon closing of the combination, which is expected to occur in mid-2020. The two companies will continue to operate as independent,